Oligonucleotide Synthesis Market Size Projected to Reach USD 12.65 Billion by 2035

According to Precedence Research, the oligonucleotide synthesis market size is valued at USD 5.39 billion in 2026 and is projected to reach approximately USD 12.65 billion by 2035, expanding at a compound annual growth rate (CAGR) of 9.95% from 2026 to 2035.

The global oligonucleotide synthesis market is witnessing significant growth, driven by increasing investments in pharmaceutical research, rising demand for gene-based therapies, and the growing prevalence of genetic disorders. This growth is a result of advancements in biotechnologies, rising focus on genetic treatments, and the ongoing collaboration between pharmaceutical companies and biopharmaceutical firms globally.

➤ Get the Full Report @ https://www.precedenceresearch.com/oligonucleotide-synthesis-market

Market Overview and Projections

The oligonucleotide synthesis market plays a crucial role in the pharmaceutical and biotechnology sectors by providing essential tools for gene-based treatments. The market size in 2025 is estimated at USD 4.90 billion, with projections for 2026 reaching USD 5.39 billion. By 2035, the market is expected to grow substantially, reaching USD 12.65 billion, driven by the increasing demand for customized therapeutics and advancements in synthetic biology.

- Market size in 2025: USD 4.90 Billion
- Market size in 2026: USD 5.39 Billion
- Market size by 2035: USD 12.65 Billion
- Compound Annual Growth Rate (CAGR): 9.95% (2026-2035)
- Forecast period: 2026-2035
- Base year: 2025

Significance of AI in the Oligonucleotide Synthesis Industry

AI is transforming the oligonucleotide synthesis industry by improving accuracy, efficiency, and speed in design and production. It accelerates drug discovery, enhances clinical trial optimization, and streamlines supply chain management. AI integration in manufacturing plants enables process optimization, real-time monitoring, and reduces human error, driving down costs and supporting high-quality, customized oligonucleotides.

For example, Intellegens' Alchemite, launched in September 2025, is an AI platform designed to accelerate the development of oligonucleotide therapies by optimizing the process development, enhancing scalability, and reducing time to market.

The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/7843

Oligonucleotide Synthesis Market Dynamics

Several key factors are fueling growth in the oligonucleotide synthesis market:

Technological Advancements: The integration of artificial intelligence (AI) in oligonucleotide synthesis is improving production accuracy, reducing costs, and enhancing the speed of therapeutic development. AI is also accelerating the drug discovery process and improving the efficiency of clinical trials.

Industry Investments: Pharmaceutical and biopharmaceutical companies are making substantial investments to expand their oligonucleotide manufacturing capacities and accelerate the development of novel therapies, particularly for rare and genetic diseases.

Rising Genetic Disorders: The increasing prevalence of genetic disorders and cancers is creating significant demand for custom oligonucleotide therapeutics, which are more precise and targeted compared to traditional treatments.

Despite the market's growth potential, challenges such as high capital investment in manufacturing facilities and the complexity of oligonucleotide synthesis methods remain key barriers to entry for new players.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Oligonucleotide Synthesis Market Segments

What Are the Key Segments in the Oligonucleotide Synthesis Market?

By Type of Product Synthesized:

The finished dosage forms segment dominated the market in 2025, due to the increasing use of oligonucleotides in the development of cancer medicines. The active pharmaceutical ingredients (API) segment is expected to see significant growth during the forecast period as the demand for oligonucleotide-based drugs rises.

By Therapeutic Area:

The rare diseases segment held the largest share of the market in 2025, driven by the growing need for precision medicine to treat genetic disorders like cystic fibrosis and Duchenne muscular dystrophy. The cardiovascular disorders segment is expected to grow at a strong CAGR due to rising cases of heart disease and the potential of oligonucleotides to offer more targeted therapies.

By Company Size:

In 2025, the large and very large companies segment accounted for 70% of the market share, as these companies have significant resources to invest in R&D and advanced manufacturing technologies. The mid-sized segment is projected to grow rapidly due to their ability to innovate and cater to niche markets, particularly in rare diseases and personalized medicine.

By Type of Oligonucleotide Synthesized:

The antisense oligonucleotide segment dominated in 2025, driven by the growing use of these oligonucleotides for gene modulation in treating a variety of diseases. The siRNA segment is expected to grow at a notable rate during the forecast period, owing to its advantages in gene silencing and potential therapeutic applications.

By Scale of Operation:

The commercial segment led the market in 2025 and is expected to continue expanding. The scalability of commercial operations allows for consistent, high-quality production that meets the growing demand for oligonucleotide-based therapies.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/7843

Oligonucleotide Synthesis Market Regional Insights

- Dominant Region: North America
- Fastest Growing Region: Asia Pacific

Why North America Dominates the Market?

North America held the largest share of the oligonucleotide synthesis market in 2025, driven by a strong pharmaceutical and biotechnology ecosystem, well‐established research infrastructure, and significant R&D investment. The region's leadership is also supported by extensive clinical trials, robust regulatory frameworks, and strong government funding for genetic and molecular research. Presence of key market players such as Agilent Technologies, Thermo Fisher Scientific, and TriLink Biotechnologies further cements its dominance.

Growth Drivers

- High adoption of advanced therapeutics and precision medicine

- Large number of ongoing genomics and oligonucleotide drug development programs

- Strong demand from pharmaceutical and biopharmaceutical companies for custom oligo synthesis

United States

The U.S. remains a major contributor to regional growth. Its advanced biotech environment, combined with high healthcare spending and strong patent protection, accelerates innovation in oligonucleotide synthesis technologies.

Emerging Growth Opportunities

Asia Pacific is expected to exhibit the highest CAGR during the forecast period, with countries like China, India, Japan, South Korea, and Australia leading growth due to increasing genetic disorder prevalence, escalating healthcare expenditure, and expanding biotech research infrastructure. Central to this trend is rising strategic interest from global market players seeking new revenue avenues within emerging markets.

Regional Strengths

- Emerging pharmaceutical and biotech hubs in China and India

- Government initiatives and investments to boost biotech manufacturing and R&D

- A growing number of local service providers and contract research organizations expanding oligo production capacity

Market Expansion Strategies

Companies are establishing collaborations and local partnerships to tap into this rapidly growing base, for example collaborations aimed at developing oligonucleotide therapeutics specific to prevalent genetic diseases in the region.

Europe: Mature Market with Strong Research Base

Market Characteristics

While Europe holds a significant market share, it generally trails North America in total revenue. Growth in Europe is driven by strong research capabilities, government funding in genomics and advanced therapeutics, and a vibrant biotech industry in countries like Germany, the UK, and France.

Key Drivers

- High uptake of oligonucleotide‐based diagnostics and personalized medicine

- Well‐established academic and research institutions supporting innovation

- Europe's mature healthcare systems and supportive regulatory environment continue to foster the development of novel oligonucleotide applications.

Oligonucleotide Synthesis Market Leading Companies

🔹Agilent Technologies
🔹Ajinomoto Bio-Pharma Services
🔹CordenPharma
🔹Creative Biolabs
🔹Ella Biotech
🔹Eurofins Genomics
🔹Future synthesis
🔹Integrated DNA Technologies
🔹Kaneka Eurogentec
🔹LGC Biosearch Technologies
🔹Merck
🔹STA Pharmaceutical/Wuxi STA
🔹Sumitomo Chemical
🔹Thermo Fisher Scientific
🔹TriLink Biotechnologies
🔹Microsynth
🔹Nitto Avecia
🔹Ribo Biotechnology

Recent Developments in the Oligonucleotide Synthesis Market

🔸Cohance Lifesciences Investment in India

In August 2025, Cohance Lifesciences made a significant investment of Rs 230 million to establish a cGMP oligonucleotide manufacturing facility in Hyderabad, India. This move aims to enhance the company's capabilities in producing high-quality oligonucleotides in compliance with current good manufacturing practices (cGMP), thereby meeting the increasing demand for oligonucleotide-based therapeutics in the region. (Source: Express Pharma)

🔸Synoligo Biotechnologies Launches E-commerce Platform

In July 2025, Synoligo Biotechnologies unveiled a new e-commerce website designed to offer high-quality oligonucleotides directly to researchers and institutions. This platform aims to streamline the purchasing process, providing a convenient solution for researchers looking for customized oligonucleotides for their studies. The new website enhances accessibility and customer experience, making oligonucleotide products more readily available to a global audience. (Source: BioSpace)

🔸Oligo Factory Expands in the U.S.

In May 2025, Oligo Factory announced the opening of a new facility in the U.S., aimed at improving its oligonucleotide synthesis capabilities. The new facility will support the production of oligo-based therapeutics, catering to the growing need for customized oligonucleotides in drug development. The expansion is expected to enhance the company's ability to meet the demands of the pharmaceutical and biotechnology industries for precision medicines. (Source: Oligo Factory)

These recent developments indicate a strong drive for expansion and innovation within the oligonucleotide synthesis market, with companies investing in new facilities, technologies, and platforms to meet the growing demand for gene-based therapies and research solutions.

Source@ https://www.precedenceresearch.com/oligonucleotide-synthesis-market

Segments Covered in the Oligonucleotide Synthesis Market

By Type of Product Synthesized

Active Pharmaceutical Ingredients
Finished Dosage Forms

By Type of Oligonucleotide Synthesized

Antisense
DNA
siRNA
Other Oligonucleotides

By Company Size

Small
Mid-sized
Large and Very Large

By Scale of Operation

Clinical
Commercial

By Therapeutic Area

Cardiovascular Disorders
Genetic Disorders
Liver Disorders
Rare Diseases
Other Disorders

By End-Users

Pharmaceutical/Biopharmaceutical Companies
Academic and Research Institutes
Hospitals

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com

🏢 707, Nandan Probiz, Baner, Pune(MH) - 411045, India

Connect With Us
📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web: https://www.precedenceresearch.com

Our Trusted Data Partners:

https://www.towardshealthcare.com/
https://www.towardspackaging.com/
https://www.towardschemandmaterials.com/
https://www.towardsfnb.com/
https://www.marketstatsinsight.com/

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:

https://www.linkedin.com/company/precedence-research
https://x.com/Precedence_R
https://www.facebook.com/precedenceresearch
https://precedence-research.medium.com/

This release was published on openPR.